Pfizer Inc. (PFE)
NYSE · Healthcare · Drug Manufacturers - General
Profile
Pfizer Inc.
- Exchange
- NYSE
- Ticker
- PFE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Key facts
Pfizer Inc.: key facts
- Pfizer Inc. (NYSE: PFE) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, Pfizer Inc. reported revenue of $62.6B and net income of $7.8B.
- Revenue fell 6.3% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $63.7B and net income was $4.3B.
MonkScore
Pfizer Inc.'s MonkScore
MonkScore
MonkScore range: 20–30
as of October 2026
Sector rank: 520 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth0–10
- Profitability40–50
- Quality60–70
- Market Conviction60–70
- Safety60–70
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Pfizer Inc.'s annual figures and the last twelve months, in USD. Last report: 28 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $63.7B | $62.6B | $63.6B | $59.6B | $101.2B | $81.3B |
| Gross profit | $46.6B | $46.5B | $45.8B | $34.6B | $66.8B | $50.5B |
| Operating income | $17.0B | $17.4B | $14.9B | $4.4B | $38.1B | $20.2B |
| Net income | $4.3B | $7.8B | $8.0B | $2.1B | $31.4B | $22.0B |
| Operating cash flow | $13.4B | $11.7B | $12.7B | $8.7B | $29.3B | $32.6B |
| Capital expenditure | -$2.4B | -$2.6B | -$2.9B | -$3.9B | -$3.2B | -$2.7B |
| Free cash flow | $11.0B | $9.1B | $9.8B | $4.8B | $26.0B | $29.9B |
| Total debt | $63.2B | $67.4B | $67.0B | $70.8B | $34.9B | $37.0B |
| Cash | $976.0M | $1.1B | $1.0B | $2.9B | $416.0M | $1.9B |
Revenue growth a year
- 1-year
- -1.6%
- 3-year
- -14.8%
- 4-year
- -6.3%
Compound growth between fiscal years.
Peers
Similar companies
- Biogen Inc.NASDAQ:BIIBMonkScore range: 50–60
- Merck & Co., Inc.NYSE:MRKMonkScore range: 60–70
- Organon & Co.NYSE:OGNMonkScore range: 60–70
- Johnson & JohnsonNYSE:JNJMonkScore range: 70–80
- Bristol-Myers Squibb CompanyNYSE:BMYMonkScore range: 80–90
- Amgen Inc.NASDAQ:AMGNMonkScore range: 90–100
- AbbVie Inc.NYSE:ABBVMonkScore range: 90–100
- Gilead Sciences, Inc.NASDAQ:GILDMonkScore range: 90–100
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
Free tools for Pfizer Inc.: Dividend calculator
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.